BioNTech SE (NASDAQ:BNTX) shares rose 2.9% on Monday after the German biotech firm reported third-quarter revenue that far exceeded expectations, even though it posted a loss where analysts had ...

After entering into a definitive agreement to acquire CureVac—who focuses on mRNA-based medicines for oncology and infectious diseases—this past June, 1 BioNTech has officially begun commenced its ...

BioNTech raised its full-year 2025 revenue guidance to €2.6-2.8 billion, up from its previous forecast of €1.7-2.2 billion and above the analyst consensus of €2.41 billion. The company also lowered ...

Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a ...

The biotech continues to embrace artificial intelligence (AI) technology, which is heartening for investors. It owns and manages an AI developer, InstaDeep. Showing their approval, those market ...

Thank you, operator. Good morning and good afternoon, everybody, and thank you for joining BioNTech's Third Quarter 2025 Earnings Call. As a reminder, the slides we'll use during the call and the ...

BERLIN, Oct 30 (Reuters) - BioNTech (22UAy.F), opens new tab, Chief Executive Ugur Sahin expects efficacy results from its late-stage trial of its potential coronavirus vaccine to be available shortly ...

FRANKFURT, Sept 17 (Reuters) - BioNTech expects that the experimental COVID-19 vaccine it is developing with Pfizer (PFE.N), opens new tab can be stored at refrigerator temperatures for at least two ...

Shares in Moderna and BioNTech have imploded since their 2021 peaks, shaving billions of dollars from their founders’ fortunes. Growing anti-vax hysteria and RFK Jr.’s FDA will likely make the ...